BullFrog AI Announces Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence
July 11 2023 - 7:00AM
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or
the "Company"), a precision medicine company using artificial
intelligence (AI) and machine learning to enable the successful
development of pharmaceuticals and biologics, today
announced the appointment of Enrique García-Rivera, Ph.D., as
its new Vice President of Artificial Intelligence. The appointment
will further advance BullFrog AI’s best-in-class proprietary
bfLEAP™ AI platform that is engineered to enable more accurate
predictions of patient disease progression and improve the design
of clinical trials to speed safe and effective drug development.
“We are excited to welcome Enrique to BullFrog
AI. His exceptional track record in AI and biomedical research,
coupled with his unique ability to translate complex data into
meaningful insights, will further bolster the capability of our
bfLEAP™ AI platform to glean insights from incomplete data sets,
perform multimodal analysis and reveal valuable patterns and
relationships across deep and wide nodes of unstructured data,”
commented Vin Singh, CEO of BullFrog AI. “I am confident that his
expertise will drive our bfLEAP™ AI platform to new heights and
strengthen our position at the forefront of AI-driven drug
development, ultimately paving the way for more effective and
personalized therapeutic solutions.”
Prior to joining BullFrog AI, Dr. García-Rivera
held leadership roles at ROME Therapeutics and nference in
Cambridge, MA. At ROME Therapeutics, he led clinical applications
and platform engineering, and while at nference, he developed a
drug discovery platform and led various research efforts.
Previously Dr. García-Rivera was a research associate at the Broad
Institute of Harvard and MIT, where he identified a novel kinase
dependency in synovial sarcomas through large-scale small molecule
profiling. His vast experience in developing machine learning
models and managing large biological databases further augments
BullFrog AI’s industry-leading capabilities.
“In a few short years, BullFrog AI has
demonstrated the potential of its bfLEAP™ AI platform to identify
new drug targets and predict patient outcomes, accelerating drug
development and enabling optimized clinical trial design,” stated
Dr. García-Rivera. “I look forward to joining such a talented team
dedicated to pushing the boundaries and fulfilling the promise of
artificial intelligence in pharmaceutical research and
development.”
Dr. García-Rivera holds a Ph.D. in Biological
and Biomedical Sciences (Chemical Biology) from Harvard University
and a BS in Interdisciplinary Sciences from the University of
Puerto Rico.
About BullFrog AI
BullFrog AI is a precision medicine company
using AI and machine learning to enable the successful development
of pharmaceuticals and biologics by predicting which patients will
respond to therapies in development. Through its collaborations
with leading research institutions, including Johns Hopkins
University, BullFrog AI is at the forefront of AI-driven drug
development using its proprietary bfLEAP™ artificial intelligence
platform. BullFrog AI is deploying bfLEAP™ for use at several
critical stages of development with the intention of streamlining
data analytics in therapeutics development, decreasing the overall
development costs by decreasing failure rates for new
therapeutics.
For more information visit BullFrog AI at:
Website: https://bullfrogai.com
LinkedIn: https://www.linkedin.com/company/bullfrogai/
Safe Harbor Statement
This press release contains forward-looking
statements. We base these forward-looking statements on our
expectations and projections about future events, which we derive
from the information currently available to us. Such
forward-looking statements relate to future events or our future
performance, including: our financial performance and projections;
our growth in revenue and earnings; and our business prospects and
opportunities. You can identify forward-looking statements by those
that are not historical in nature, particularly those that use
terminology such as "may," "should," "expects," "anticipates,"
"contemplates," "estimates," "believes," "plans," "projected,"
"predicts," "potential," or "hopes" or the negative of these or
similar terms. In evaluating these forward-looking statements, you
should consider various factors, including: our ability to change
the direction of the Company; our ability to keep pace with new
technology and changing market needs; and the competitive
environment of our business. These and other factors may cause our
actual results to differ materially from any forward-looking
statement. Forward-looking statements are only predictions. The
forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives, may
not occur, and actual events and results may differ materially and
are subject to risks, uncertainties, and assumptions about us. We
are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Contact:
InvestorsDave GentryRedChip Companies,
Inc.BFRG@redchip.com800-733-2447
MediaTiberend Strategic Advisors, Inc.Eric
ReissEreiss@tiberend.com802-249-1136
Dave SchemeliaDschemelia@tiberend.com609-468-9325
SOURCE: BullFrog AI Holdings,
Inc.
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bullfrog AI (NASDAQ:BFRGW)
Historical Stock Chart
From Jul 2023 to Jul 2024